Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 79Lymphoma 62Breast Neoplasms 61Prostatic Neoplasms 60Multiple Myeloma 60Lung Neoplasms 55Neoplasm Metastasis 54Ovarian Neoplasms 47Leukemia, Myeloid, Acute 47Colorectal Neoplasms 41Hematologic Neoplasms 40Melanoma 39Carcinoma, Non-Small-Cell Lung 38Pancreatic Neoplasms 31Lymphoma, Non-Hodgkin 31Glioma 31Brain Neoplasms 30Urinary Bladder Neoplasms 28Myelodysplastic Syndromes 28Sarcoma 26Carcinoma, Renal Cell 26Glioblastoma 25Fallopian Tube Neoplasms 25Neuroblastoma 23Triple Negative Breast Neoplasms 22Leukemia, Lymphocytic, Chronic, B-Cell 22Burkitt Lymphoma 21Stomach Neoplasms 19Small Cell Lung Carcinoma 19Squamous Cell Carcinoma of Head and Neck 18

Interventions

relatlimab 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Cystoscopy 1Circulating Tumor DNA 1Cell-Free Nucleic Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Muscle Invasive Bladder Urothelial Carcinoma × 1 year × Clear all
NCT05987241 2026-06-03

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

National Cancer Institute (NCI)

Phase 2/3 Recruiting
992 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡